21 completed. 21 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 21 |
Follow Chickenpox: new trials by email Literature Review of Chickenpox trials Research Report on Chickenpox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine - Measles; Mumps; Rubella; Chickenpox, Measles | Phase 2 | Completed | GlaxoSmithKline | 801 | 2022-12-14 | 2025-06-22 |
| A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency - Chickenpox | Phase 2 | Completed | GlaxoSmithKline | 800 | 2022-02-03 | 2025-02-28 |
| Systems Biology of Zoster Vaccine Shingrix® - Zoster, Zoster Varicella | Phase 2 | Completed | Emory University | 38 | 2019-11-14 | 2024-07-30 |
| The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age NBP608, Varivax - Varicella | Phase 2 | Completed | SK Chemicals Co., Ltd. | 152 | 2016-05-01 | 2017-04-14 |
| Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), GSK Biologicals' 208136, new formulation - Measles, Varicella | Phase 2 | Completed | GlaxoSmithKline | 501 | 2009-06-03 | 2019-11-15 |
| Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy ZOSTAVAX, Placebo - Herpes Zoster, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 395 | 2009-04-29 | 2021-11-04 |
| Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years Herpes zoster vaccine GSK1437173A, Placebo - Herpes Zoster | Phase 2 | Completed | GlaxoSmithKline | 410 | 2009-01-12 | 2019-06-26 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix® - Varicella, Rubella | Phase 2 | Completed | GlaxoSmithKline | 1851 | 2007-11-20 | 2018-10-09 |
| Study of Two Formulations of GSK Biologicals' Varicella Vaccine Varilrix (inactivated varicella vaccine) - Varicella | Phase 2 | Completed | GlaxoSmithKline | 244 | 2007-11-01 | 2018-06-08 |
| Month 30 & 42 Extension Studies of CRD-004 Primary Study Blood sampling for assay of persistence of immunogenicity - Herpes Zoster | Phase 2 | Completed | GlaxoSmithKline | 34 | 2007-06-25 | 2019-06-26 |
| An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN). placebo, carisbamate - Postherpetic Neuralgia, Neuralgia | Phase 2 | Completed | SK Life Science, Inc. | 91 | 2007-03-01 | 2018-05-01 |
| Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects Herpes Zoster vaccine GSK1437173A Low Dose, Herpes Zoster vaccine GSK1437173A Medium Dose, Herpes Zoster vaccine GSK1437173A High Dose - Herpes Zoster | Phase 2 | Completed | GlaxoSmithKline | 715 | 2007-02-14 | 2019-03-15 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ MeMuRu-OKA (study vac), MMR, Varicella vacc (control) - Mumps, Rubella | Phase 2 | Completed | GlaxoSmithKline | 400 | 2006-04-01 | 2016-10-07 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ MeMuRu-OKA (study vacc), MMR, Varicella vacc (control) - Varicella, Rubella | Phase 2 | Completed | GlaxoSmithKline | 446 | 2006-03-01 | 2016-10-07 |
| Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). VarilrixTM - Varicella | Phase 2 | Completed | GlaxoSmithKline | 45 | 2003-09-08 | 2018-11-08 |
| Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain Capsaicin Patch - Neuralgia, Pain | Phase 2 | Completed | NeurogesX | 42 | 2002-03-01 | 2006-02-07 |
| Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live - Measles, Mumps | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1210 | 2001-12-01 | 2017-03-15 |
| Shingles: Immune Effects of Tai Chi Tai Chi Chih - Aging, Herpes Zoster | Phase 2 | Completed | National Institute on Aging (NIA) | 140 | 2001-07-01 | 2009-12-11 |
| ProQuad Dose Selection Study (V221-011)(COMPLETED) Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: M-M-R II, Comparator: PUVV - Measles, Mumps | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1551 | 1999-04-01 | 2015-04-10 |
| Tai Chi Chih and Varicella Zoster Immunity Tai chi chih - Varicella | Phase 2 | Completed | National Center for Complementary and Integrative Health (NCCIH) | 70 | 2006-08-18 |
Showing 20 of 21. Sign in to see all of them.
Herpes Zoster (9) · Measles (7) · Mumps (7) · Rubella (7) · HIV Infections (2) · Neuralgia (2) · Neuralgia, Postherpetic (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Blister (1) · Depression (1) · Exanthema (1) · Hyperalgesia (1) · Pain (1)
DNA Virus Infections (21) · Herpesviridae Infections (21) · Infections (21) · Varicella Zoster Virus Infection (21) · Virus Diseases (21) · RNA Virus Infections (9) · Mononegavirales Infections (7) · Morbillivirus Infections (7) · Mouth Diseases (7) · Paramyxoviridae Infections (7) · Parotid Diseases (7) · Parotitis (7) · Rubivirus Infections (7) · Rubulavirus Infections (7) · Salivary Gland Diseases (7)
measles, mumps, rubella, varicella vaccine (3) · Hepatitis A Vaccines (2) · Measles-Mumps-Rubella Vaccine (2) · Acyclovir (1) · Blood Specimen Collection (1) · Chickenpox Vaccine (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Herpes Zoster Vaccine (1) · Rubella Vaccine (1) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (1) · Sodium Chloride (1) · sorivudine (1)
GlaxoSmithKline (11) · Merck Sharp & Dohme LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Emory University (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · National Institute on Aging (NIA) (1) · NeurogesX (1) · SK Chemicals Co., Ltd. (1) · SK Life Science, Inc. (1)
United States (10) · Czechia (3) · Taiwan (3) · Germany (2) · Italy (2) · Puerto Rico (2) · Australia (1) · Belgium (1) · Canada (1) · Colombia (1) · Estonia (1) · France (1) · Hungary (1) · Latvia (1) · Netherlands (1)
Constance A. Benson, MD (1) · Crumpacker C (1) · Jeffrey L. Lennox, MD (1) · John A Jermano (1) · Michael R. Irwin, MD (1) · Nadine Rouphael, MD (1)
PMID 16094218, PMID 18652095, PMID 21934474, PMID 22872734, PMID 25272081, PMID 26762528, PMID 29461919, PMID 29590326, PMID 30975567, PMID 41825190
2008 (1), R01AG018367 (1), U19AI090023 (1)